drugset / Trial / NCT06270576

Nasal Inflammation Following Endotoxin Challenge in Patients With Asthma

NCT06270576

Phase 1 Not yet recruiting 60 enrolled National Jewish Health
Non-randomizedParallel-groupOpen-labelBasic science

Summary

A phase I clinical research study aimed at determining mechanisms that regulate airway mucosal inflammation in asthma endotypes using intranasal administration of endotoxin (lipopolysaccharide from E. coli) in healthy controls and subjects diagnosed with asthma.

Timeline

Start
2024-04
Primary completion
2028-04
Completion
2028-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lipopolysaccharide Other / unclassified Intranasal

Indications